Dror Ortho-Design, Inc. (“Dror” or the “Company”) (OTC PINK: DROR), a pioneer in artificial intelligence orthodontic solutions, today announced the successful completion of a user experience trial for its ZSmile platform prior to commercial launch.
This comprehensive user experience trial evaluated the platform’s usability for patients, orthodontists, and dental professionals under real-world operating conditions.
The trial focused on user interaction with the system and complemented previous clinical trials that demonstrated the efficacy of Dror’s Smile Treatment System. Dror’s first-generation system received FDA approval in 2020 and has successfully treated more than 250 patients in Israel and Europe.
“The successful completion of this usability trial validates the intuitive design of our second-generation solution and the seamless experience it provides to patients and physicians. In addition to confirming its ease of use, the trial demonstrated the comfort of ZSmile and its lack of disruption to normal sleep,” said Lee Haddad, CEO of Dror.
“We invested two years developing an advanced remote monitoring and patient management system, culminating in a platform that tracks treatment adherence in real time while providing important and engaging feedback to all users.
These trial results are helping us finalize the commercial version in preparation for production and distribution, which is subject to regulatory approval in the first half of 2025.”
The company has incorporated all feedback from the user experience trial and is completing the regulatory process to begin manufacturing and distributing ZSmile in Israel in the first half of 2025.
Dr. Joel Becker, DMD, MSc, is a board-certified dentist at Hadassah Dental College and an orthodontic consultant at Dror Dental Clinic.
He commented, “With three decades of orthodontic practice, and having worked with a variety of treatment modalities from traditional braces to clear aligners, I believe ZSmile is a significant technological advancement.
The system’s ability to effectively address Class I and Class II malocclusions, minimize discomfort, and maximize maneuverability addresses a critical need in the market.”
In another survey conducted through a third-party service, the company surveyed 1,000 randomly selected clear aligner patients.
The survey results showed that 74% felt their aligners interfered with daily activities such as eating and speaking in public, 77% felt uncomfortable while wearing them, and 93% said they preferred aligners that were worn at night to gently move teeth while sleeping.
Related topics:
